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Incidence of thrombotic complications in patients with
haematological malignancies with central venous catheters: a
prospective multicentre study
The use of a central venous catheter (CVC) to facilitate the
delivery of medications and of nutritional support has become
increasingly frequent in a number of acute and chronic clinical
conditions. However, benefits from CVC can be offset by
complications associated with their use, such as thrombosis
and infections, which may threaten the patient and/or impair
CVC functioning (Verso & Agnelli, 2003). Many studies have
addressed the incidence, associated risk factors and role of
antithrombotic prophylaxis in patients with solid tumours, but
only few data are available on haematological patients who
often have severe thrombocytopenia (Cortelezzi et al, 2003;
Couban et al, 2005). The latter might decrease the risk of
thrombosis, but, on the contrary, increase bleeding and
perhaps contraindicate the use of antithrombotic prophylaxis.
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Summary
This prospective, observational and multicentre study assessed the incidence
of, and risk factors for, symptomatic venous thrombotic complications after
central venous catheter (CVC) positioning in patients with haematological
malignancies. A total of 458 consecutive CVC insertions were registered in
416 patients (81Æ2% of whom had severe thrombocytopenia). Over the
observation period (3 months or up to catheter removal), the incidence of
events was: CVC-related deep vein thrombosis (DVT), 1Æ5%; lower limb
DVT, 0Æ4%; pulmonary embolism (PE), 1Æ3%; fatal PE, 0Æ6%; CVC-related
superficial thrombophlebitis, 3Æ9%; CVC-occlusion/malfunction of
thrombotic origin, 6Æ1%; major arterial events, 1Æ1%. Severe bleeding and
CVC-related infections were observed in 3Æ5% and 4Æ6% of cases respectively.
A composite end point (any venous thromboembolism or superficial
thrombophlebitis or CVC occlusion/malfunction) was defined in order to
consider venous thrombotic events with a significant impact on clinical
practice. With this criterion, the overall incidence was 12Æ0% (2Æ54 cases/1000
catheter days). No factor helped to predict venous thrombotic complications:
only thrombocytopenia was associated with a weak trend for a reduced risk
(odds ratio 0Æ52; 95% confidence interval 0Æ26–1Æ07). No severe bleeding was
observed in those patients who received antithrombotic prophylaxis. This
study shows that the impact on clinical practice of symptomatic CVC-related
thrombotic complications is not negligible in patients with haematological
malignancies.
Keywords: central venous catheter, haematological malignancies, thrombo-
sis, thrombocytopenia, antithrombotic prophylaxis.
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The primary aim of this prospective, multicentre and obser-
vational study was to assess the incidence of, and risk factors
for, symptomatic thrombotic complications after CVC posi-
tioning in patients with haematological malignancies.
Patients and methods
Elegible patients
Consecutive patients with haematological malignancies aged
more than 18 years who underwent CVC positioning were
eliglible for the study. Patients were prospectively followed-up
from CVC insertion for 3 months or up to CVC removal,
whichever came first. All types of CVCs were allowed,
including tunnelized and non-tunnelized, centrally inserted,
totally implanted and peripherally inserted devices, with both
single and double lumen.
Design of the study
This study was performed between May 2002 and June 2003 in
eight Italian Haematology Units. Each unit was allowed to use
its own protocol for CVC care, defined and adopted prior to
starting the study. The use of antithrombotic prophylaxis was
left to the investigators’ choice. Each CVC-positioning was
considered as a single case for the study, so that a patient who
had completed the scheduled observation period was registered
as a new case for the study if another CVC was inserted. The
study protocol was approved by Institutional Review Boards
and participating patients gave written informed consent.
Events registered during the follow-up period were: deep
vein thrombosis (DVT) of the upper limbs, DVT of lower
limbs, pulmonary embolism (PE), CVC-related superficial
thrombophlebitis, CVC occlusion/malfunction of thrombotic
origin, atherothrombotic events (myocardial infarction, stroke
and peripheral thromboembolism), bloodstream infections
and CVC-related bloodstream infections, severe bleeding and
death. Clinically suspected DVT and PE had to be confirmed
by objective criteria (compression ultrasonography or venog-
raphy, lung scan or computed tomography scan). CVC-related
superficial thrombophlebitis was defined as the occurrence of
signs/symptoms of inflammation along a superficial vein.
CVC-occlusion/malfunction was defined as persistent pain
during infusion or impossibility for sampling and/or infusion
occurring after at least 24 h of initial adequate CVC function
that was not reversible after at least two flushes with saline. In
case of failure, low-dose urokinase was used. Malfunction/
occlusion was attributed to thrombosis when other possible
causes (i.e. kinking or rupture) were excluded. In order to
consider thrombotic events with an impact on daily clinical
practice, all DVTs or PE, superficial thrombophlebitis and
CVC occlusion/malfunction attributable to thrombosis were
included in a composite end point (one event considered for
each case). As commonly accepted criteria for major bleeding,
which include blood transfusion requirement, might be
misleading in these patients, because of the type of disease
and the frequent need for transfusions independently of
haemorrhagic episodes, severe bleeding was defined as causing
hospitalization, prolongation of hospital stay, or if it was life-
threatening or fatal. Infections were classified and registered as
bloodstream infections or CVC-related bloodstream infections
as previously reported (Cortelezzi et al, 2003). All deaths were
reviewed by an independent adjudication committee that
evaluated a possible relationship with thromboembolic com-
plications.
A dedicated electronic database was developed and used to
collect the patients’ main characteristics, including the disease
under treatment, previous history of thrombosis and pertinent
laboratory data. Detailed information on CVC positioning
(type of CVC, order of CVC insertion–first, second and more
than second, side and site of insertion, tip position and
possible positioning-related complications) were also collected.
During the follow-up, the reasons for using CVC (infusion,
sampling and apheresis), duration of daily use and deviations
from planned procedures of CVC care were recorded.
Chemotherapy, anti-infective or anti-thrombotic drugs, trans-
fusions, total parenteral nutrition, infusion of peripheral stem
cells, both through CVC and/or other routes of administration,
were also recorded. Daily dosages >5000 UI of unfractionated
heparin, low molecular weight heparins or antiplatelet drugs
were considered antithrombotic prophylaxis, whereas flushing
of CVC with unfractionated heparin at doses of <5000 IU/d
was not. Information on the occurrence, duration and severity
of thrombocytopenia (platelet count<50 · 109/l or<10 · 109/l)
and/or neutropenia (<0Æ5 · 109/l and <0Æ1 · 109/l) were
recorded.
Statistical analysis
The sample size was computed according to the primary study
objective that is merely descriptive. A total of 450 implanted
catheters was calculated as necessary to provide a reliable
estimate of the incidence of symptomatic thrombotic events
(composite end point), by hypothesizing an event rate of 10%,
with 95% confidence intervals (CI) of the estimate equal to the
event rate ±2Æ5%. Assuming a ratio of catheters per patient
equal to 1Æ1 during the period of survey, a sample size of 410
patients was computed. Descriptive statistics refer to all
included cases. For continuous variables, the mean, standard
deviation, median, minimum value and maximum value were
calculated. For each discrete variable the number of cases in
each category with missing or non-missing values, in relation
to all cases with non-missing values of that variable, was
calculated. The relationship of the composite study end point
with covariates was investigated by means of univariate and
multivariate logistic regressions with generalized estimating
equation (GEE) approach and exchangeable correlation matrix
in order to take into account clustered data (two or more
catheters implanted in the same patient). The number and type
of covariates included into the multivariate model were
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selected according to the usual rule of thumb (no more than
one covariate for 10 events) and based to prior knowledge
about their clinical relevance, regardless of univariate and
subset selection findings (epidemiological approach). Covari-
ates included in the multivariate logistic regression were: type
of CVC, use of antithrombotic prophylaxis, occurrence of
thrombocytopenia (<50 · 109/l) and catheter-related infec-
tion. Univariate analyses were performed to relate the afore-
mentioned composite end point with the same covariates
considered for the multivariate analysis, plus age group (£50,
51–64, ‡65 years), gender, prior thrombosis, order of CVC
insertion, high-dose chemotherapy, apheresis, stem-cell infu-
sion, total parenteral nutrition and occurrence of bloodstream
infection. Odds ratios (ORs) and 95% CI were reported with
two-tailed probability (P) values. Statistical calculations were
carried out using sas version 8Æ2. A two-tailed P-value of 0Æ05
was used to define statistical significant results.
Results
Study population
A total of 458 cases of CVC positioning in 416 patients were
entered in the study. Baseline demographic and haematological
characteristics, underlying diseases and phases of treatment of
the patients are shown in Table I. Previous thrombotic events
were reported in 47 (10Æ3%) and mediastinal bulk in 25 (5Æ5%)
of the cases. Thrombocytopenia (<50 · 109/l) was present in
81Æ2% of cases, with a mean overall duration of 19Æ2 (±15Æ5) d,
severe thrombocytopenia (<10 · 109/l) in 53Æ2% of cases, with
a mean overall duration of 5Æ6 (±6Æ8) d. Neutropenia
(<0Æ5 · 109/l or <0Æ1 · 109/l) occurred in 69Æ2% and 59Æ8%
of cases, lasting for a mean of 15Æ4 (±13Æ1) and 9Æ7 (±9Æ1) d
respectively.
CVC positioning and use
Non-tunneled CVCs were the most frequently used type of
catheters (65Æ9 %), peripherally inserted central catheters
(PICCs) and port devices being used in a smaller number of
cases (2Æ8% and 1Æ7 %) and tunneled in the remaining ones
(29Æ6%). In 189 cases (41Æ3%) a CVC had been already
positioned and removed at least once in the same patient.
Jugular and subclavian veins were the site of access in
49Æ1% and 43Æ0% of the insertions respectively; the right side
was used in 79Æ7% of cases. In 54Æ5% of cases the catheter tip
was positioned at the level of the cava vein, in 34Æ9% at the
atrio-cava junction. The order of CVC positioning was: first
in 58Æ7%, second in 19Æ2% and more than second in 22Æ1%.
CVC was used for drug infusion in 96Æ7%, for sampling in
91Æ0%, for transfusions in 81Æ6%, for total parenteral
nutrition in 40Æ6%, and for apheresis in 15Æ6% of cases.
Mean (±SD) duration of CVC daily use (single or multiple
periods for each case) was 25Æ7 (±17Æ0) d. Complications in
CVC positioning were reported in 44 cases (9Æ6%), the most
frequent being haematomas at the insertion site (17 cases,
3Æ7%). Central venous catheter malfunction at positioning in
10 cases and arterial puncture in eight cases (four of them
inducing local haematoma) necessitated the need for revision.
In one patient CVC insertion was complicated by pneumo-
thorax.
Antithrombotic prophylaxis and other treatments
Antithrombotic prophylaxis was used in 65 cases (14Æ2%): low
molecular weight heparin in 53 cases (11Æ6%); unfractionated
heparin, antiplatelet agents and oral anticoagulants in six, five
and one cases respectively. In 22 cases (4Æ8%) prophylaxis was
given to patients who had previously suffered thrombotic
events. Antibiotic prophylaxis was used in the great majority of
patients included in the study to prevent bacterial, micotic or
viral infections. Patients received high-dose or conventional
dose chemotherapy in 179 (39Æ1%) and 195 (42Æ6%) cases,
respectively, or both in 21 (4Æ6%) cases. Chemotherapy was
administered through CVC in 98Æ7% of cases. Blood transfu-
sions were required in 383 cases (83Æ6%), whilst 185 (40Æ4%)
cases underwent total parenteral nutrition through the CVC.
Peripheral stem cells were infused in 132 cases (28Æ8%), 112 of
them (24Æ4%) through the CVC.
Infection and bleeding
The incidence of bloodstream infections and CVC-related
bloodstream infections in the study population was 15Æ1% and
Table I. Patient characteristics at baseline, underlying haematological
disease, and phase of treatment.
Patient characteristics (median, ranges)
Age (years) 53 (18–87)
Gender (M/F) (n) 231/227
Weight (kg) 68 (40–126)
Neutrophils (·109/l) 2.5 (0–94.4)
Platelets (·109/l) 137.0 (0.1–894.0)
Haemoglobin (g/dl) 11.0 (5.0–17.0)
Disease n (%)
Acute lymphatic leukaemia 47 (10.3)
Acute myeloid leukaemia 130 (28.4)
Chronic myeloid leukaemia 7 (1.5)
Multiple myeloma 86 (18.8)
Non-Hodgkin’s lymphoma 107 (23.4)
Hodgkin’s disease 18 (3.9)
Other 63 (13.7)
Phase of treatment, n (%)
Induction 117 (25.6)
Consolidation 51 (11.1)
Salvage 73 (15.9)
Autologous-SCT 81 (17.7)
Allogeneic-SCT 35 (7.6)
Miscellaneous 101 (22.1)
SCT, stem-cell transplantation.
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4Æ6% respectively. Severe bleeding events occurred in 16 cases
(3Æ5%); in three patients bleeding (cerebral) was fatal. Sites and
types of bleeding episodes were the followings: intracranial
(seven cases), CVC insertion site (five), haematoma (two),
intraperitoneal and multiorgan because of disseminated intra-
vascular coagulation in one patient each. Two of the 16
patients with severe bleeding were receiving antithrombotic
prophylaxis, but none of those who died of intracerebral
bleeding was receiving antithrombotic prophylaxis.
Thrombotic complications
The incidence of thrombotic events is reported in Table II.
CVC-related upper limb DVT was followed by CVC removal
in four of seven cases; malfunction/occlusion of thrombotic
origin was observed in 28 cases and was followed by CVC
removal in 11 of them. Seven cases of PE (three fatal) were
observed, one (non fatal) being concomitant with CVC-related
DVT.
Composite end point
Figure 1 shows the incidences of events, obtained by adding
progressively the clinically relevant complications. Column C
represents a composite end point combining all the CVC-
related venous thrombotic complications, and this end point
was considered for univariate (Table III) and multivariate
analyses (Table IV). None of the variables selected for statis-
tical analysis was significantly related to the occurrence of
venous thrombotic complications. However, thrombocytop-
enic patients tended to have a lower risk of thrombotic events,
close to statistical significance (OR 0Æ52; 95% CI 0Æ26–1Æ07 –
multivariate analysis). In Fig 2 the time distribution of venous
thrombotic events (column C, Fig 1) is reported. The great
majority of events occurred within the first 20 d after catheter
insertion.
Table II. Incidence of thrombotic events.
Events Percentage
Number of
events/1000
catheter-days
CVC-related DVT 1Æ5 (0) 0Æ32
Lower limb DVT 0Æ4 (0) 0Æ09
Total PE/fatal PE 1Æ3 (0)/0Æ6 (0) 0Æ28/0Æ14
Superficial thrombophlebitis 3Æ9 (0Æ2) 0Æ83
CVC-malfunction/occlusion
of thrombotic origin
6Æ1 (1Æ1) 1Æ29
Atherothrombotic events 1Æ1 (0Æ4) 0Æ23
CVC, central venous catheter; DVT, deep vein thrombosis; PE, pul-
monary embolism. The percentage of events in patients receiving
antithrombotic prophylaxis are shown in parentheses.
Fig 1. Composite incidence (%) of clinically relevant complications.
Column C represents the clinical end point considered for univariate
and multivariate analyses.
Table III. Relationship between variables and thrombotic complica-
tions: univariate analyses (for type of catheter, ‘other’ denotes
peripherally inserted central catheter or port).
Variable Effect
Odds
ratio 95% CI
Age 51–64 vs. £50 years 0Æ70 0Æ38–1Æ28
‡65 vs. £50 years 0Æ82 0Æ34–1Æ94
Gender Male vs. female 0Æ86 0Æ49–1Æ51
Previous thrombosis Yes vs. no 1Æ59 0Æ70–3Æ59
Type of catheter Non-tunnelled vs.
tunnelled
1Æ49 0Æ74–3Æ01
Other vs. tunnelled 0Æ47 0Æ06–3Æ98
Order of CVC
positioning
II vs. I 1Æ49 0Æ74–3Æ00
>II vs. I 1Æ38 0Æ71–2Æ72
High-dose
chemotherapy
Yes vs. no 0Æ94 0Æ54–1Æ63
Apheresis Yes vs. no 1Æ23 0Æ60–2Æ52
Stem-cell infusion Yes vs. no 0Æ85 0Æ44–1Æ62
Total parenteral
nutrition
Yes vs. no 0Æ98 0Æ57–1Æ71
Antithrombotic
prophylaxis
Yes vs. no 0Æ71 0Æ30–1Æ70
Thrombocytopenia Yes vs. no 0Æ57 0Æ30–1Æ10
BSI Yes vs. no 1Æ16 0Æ55–2Æ48
Catheter-related BSI Yes vs. no 0Æ76 0Æ17–3Æ37
BSI, blood stream infection; CI, confidence intervals; CVC, central
venous catheter.
Table IV. Relationship between variables and thrombotic complica-
tions: multivariate logistic regression analysis (for type of catheter,
‘other’ denotes peripherally inserted central catheter or port).
Variable Effect
Odds
ratio 95% CI
Type of catheter Non-tunnelled vs.
tunnelled
1Æ65 0Æ79–3Æ43
Other vs.
tunnelled
0Æ45 0Æ05–4Æ43
Antithrombotic
prophylaxis
Yes vs. no 0Æ69 0Æ28–1Æ70
Thrombocytopenia Yes vs. no 0Æ52 0Æ26–1Æ07
Catheter-related BSI Yes vs. no 0Æ80 0Æ18–3Æ69
BSI, blood stream infection; CI, confidence intervals.
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Follow-up
The mean observation period was 47Æ2 ± 35Æ2 d. In 156 cases
(34Æ1%) the planned observation period of 3 months was
achieved. In 177 cases (38Æ6%) CVC was removed because it
was no longer used before the end of the planned observation
period. CVC removal for thrombotic or infectious complica-
tions occurred in 47 cases (10Æ2%, in 16 cases because of
thrombotic events, in 31 because of infection). Four patients
were lost to follow-up (0Æ9%). Interruption of the study
occurred in 22 cases (4Æ8%) and it was related to other reasons
(i.e. removal of the CVC caused by accidental events, or local
side effects at the insertion site). Fifty-two patients (11Æ3%)
died during the scheduled observation period: in three cases
death was caused by an acute thrombotic complication
(objectively documented fatal PE). In the remaining patients,
death was because of disease progression and/or other disease-
related complications.
Discussion
In adult patients with malignancy the reported incidence of
clinically overt CVC-related venous thrombosis ranges from
0Æ3% to 28Æ3% (0Æ02–0Æ92 events/1000 catheter days) (Bona,
1999; Verso & Agnelli, 2003). In a recent meta-analysis (Klerk
et al, 2003) the incidence of thrombosis varied between 0%
and 20% when symptomatic thrombosis was considered, and
between 27% and 90% when thrombosis was objectively
diagnosed. The majority of objectively detected thrombi were
clinically silent (Lokich & Becker, 1983; Bern et al, 1990;
Balestrieri et al, 1995; Monreal et al, 1996; De Cicco et al,
1997; Franck et al, 2000; Glaser et al, 2001) and non-
occlusive (Martin et al, 1999). CVC-related thrombosis was
evaluated mainly in patients with solid tumours, but fewer
data are available in patients with haematological malignancy
(Couban et al, 2005). Data on CVC-related complications in
haematological patients had been obtained mainly from
retrospective studies of small sample size, whereas in this
prospective observational, multicentre study the incidence of
clinically overt thrombotic complications was evaluated in a
large cohort of consecutive haematological patients with
CVC.
We arbitrarily chose a cumulative end point of clinically
significant thrombotic events (including DVT, superficial
thrombophlebitis, and occlusion/malfunction), because these
symptomatic events have a remarkable impact on the daily
clinical practice in haematological patients. Our choice to look
only for symptomatic events was driven by the consideration
that the clinical relevance of asymptomatic CVC-related
thrombosis is still debated and regular screening with objective
tests is generally not recommended.
In this study an incidence of 12% of thrombotic events, as
previously defined, was recorded; 3Æ2% were major events such
as DVT and/or PE. However, in our experience, even a minor
event, such as a CVC occlusion, had a significant impact on the
clinical management of these patients. The relatively low
incidence of major thrombotic events in our registry may be
explained by the fact that patients were enrolled in haemato-
logical units with teams experienced in CVC positioning and
care. Each haematology unit had written procedures (collected
and reviewed before the start of enrolment) that were strictly
followed during the observation period. In 64Æ2% of the cases,
CVCs were positioned in the surgical room under sterile
conditions and CVC insertion was controlled radiologically in
84Æ9% of patients. The CVCs with higher thrombotic (PICCs)
(Cortelezzi et al, 2003) and haemorrhagic risks (totally
implantable) (Johansson et al, 2004) were used in a very small
proportion of patients (4Æ5%). The majority of venous
thrombotic events (72Æ7%) occurred within 1 month from
CVC-positioning, with a median interval of 19 d after CVC
placement, a timing consistent with previous findings (van
Rooden et al, 2003).
In this study, no predictive factors seemed to influence the
occurrence of venous thrombotic complications, at variance
with other findings suggesting a role for type of catheter, high-
dose chemotherapy, apheresis (Haire et al, 1990, 1991; Conlan
et al, 1991; Sletnes et al, 1996), or infections (Raad, 1998).
However, it should be noted that only a minority of patients
used the CVCs at higher thrombogenic potential. Thrombo-
cytopenia was associated with a trend for reduced risk of
thrombotic complications. However, >10% of severely
thrombocytopenic patients had an episode of venous throm-
bosis, and three of six cases of pulmonary embolism occurred
in thrombocytopenic patients.
The use of routine antithrombotic prophylaxis to prevent
CVC-related thrombosis is still debated (Klerk et al, 2003;
Geerts et al, 2004). Although some studies carried out in
patients with tumours have shown a benefit of prophylaxis with
low molecular weight heparin or fixed low-dose warfarin (Bern
et al, 1990; Monreal et al, 1996; Boraks et al, 1998), other
studies did not confirm these results (Heaton et al, 2002;
Reitchard et al, 2002;Massicotte et al, 2003; Couban et al, 2005;
Verso et al, 2005), so that no definite recommendations are
currently available (Verso & Agnelli, 2003). Haematological
patients may differ from patients with solid tumours because
Fig 2. Time-distribution of venous thrombotic complications inclu-
ded in the composite end point (d ¼ days).
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they present more frequently with severe thrombocytopenia.
This may decrease the risk of thrombosis but may increase that
of bleeding. In this study 14Æ2% of patients received antithrom-
botic prophylaxis, mainly low molecular weight heparin. The
decision of using antithrombotic drugs was left to the attending
physician. Antithrombotic prophylaxis was not associated with
an increased incidence of severe bleeding. However, it should be
kept in mind that this study was not planned to give an answer
on the efficacy and safety of antithrombotic prophylaxis in
haematological patients with CVC.
In conclusion, our survey provides information on the
incidence of clinically overt thrombotic complications in
patients with haematological malignancies with a CVC, showing
that they remain a clinical problem. Future studies may utilize
the cumulative clinical end point developed in this prospective
registry in order to test the efficacy of drugs or of other tools
meant to reduce the incidence of clinically relevant CVC-related
thrombotic complications in haematological patients.
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